The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins
Abstract
Although designed covalent inhibitors as drug candidates offer several unique advantages over conventional reversible inhibitors, including high potency and the potential for less frequent dosing, there is a general tendency to avoid the covalent mode of action in drug discovery programs due to concerns regarding immune-mediated toxicity that can arise from indiscriminate reactivity with off-target proteins. Therefore, the ability to assess off-target reactivity relative to target specificity is desirable for optimizing covalent drug candidates in the early discovery stage. One concern with current surrogate nucleophile trapping approaches is that they employ a simplistic model nucleophile such as glutathione, which may not reliably reflect the covalent interactions with cellular or extracellular proteins. One way to get a more relevant reactivity assessment is to directly measure the ability of an inhibitor to covalently modify nucelophilic amino acids on biologically relevant proteins, both on- and off-target. In this article, we describe a label-free bottom-up proteomic workflow for simultaneous evaluation of target binding and off-target reactivity of covalent drug candidates to selected proteins at the peptide level. Ibrutinib, a covalent drug targeting the active site of BTK protein, was used as a model compound to demonstrate the feasibility of the workflow. The compound was incubated with a mixture of target protein, Bruton's tyrosine kinase (BTK), and two abundant proteins in blood, hemoglobin (Hb) and human serum albumin (HSA), and then the ibrutinib modification sites were determined utilizing a bottom-up proteomic approach. A non-BTK specific model compound (1) known to modify cysteine residues was also included. By comparing the extent of off-target modifications to the targeted BTK C481 binding in a wide compound concentration range, we were able to determine the concentration where maximum target binding was achieved with minimal off-target reactivity. The generic label-free bottom-up proteomics workflow described in this article should be useful in the rank order assessment of off-target reactivity vs on-target reactivity of covalent drug candidates in the early drug discovery stage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In some clinical trials, immunogenicity was observed several weeks or months after treatment with covalent drugs [135, 136].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [136]
Citations
Cites
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Crystal structure of human serum albumin at 2.5 Å resolution
Sugio, S., Kashima, A., Mochizuki, S., Noda, M., & Kobayashi, K. (1999) · Protein Engineering, Design and Selection · doi:10.1093/protein/12.6.439 · Cited by 1,786
Profiling Enzyme Activities In Vivo Using Click Chemistry Methods
Speers, A. E., & Cravatt, B. F. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.012 · Cited by 774
The thiol pool in human plasma: The central contribution of albumin to redox processes
Turell, L., Radi, R., & Alvarez, B. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.050 · Cited by 708
Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.02.013 · Cited by 439
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
Lanning, B. R., Whitby, L. R., Dix, M. M., Douhan, J., Gilbert, A. M., Hett, E. C., Johnson, T. O., Joslyn, C., Kath, J. C., Niessen, S., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1582 · Cited by 359
Wissner, A., Overbeek, E., Reich, M. F., Floyd, M. B., Johnson, B. D., Mamuya, N., Rosfjord, E. C., Discafani, C., Davis, R., Shi, X., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020241c · Cited by 264
Huth, J. R., Mendoza, R., Olejniczak, E. T., Johnson, R. W., Cothron, D. A., Liu, Y., Lerner, C. G., Chen, J., & Hajduk, P. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0455547 · Cited by 228
Adductomics: Characterizing exposures to reactive electrophiles
Rappaport, S. M., Li, H., Grigoryan, H., Funk, W. E., & Williams, E. R. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2011.04.002 · Cited by 180
Cited by
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
Approaches to mitigate the risk of serious adverse reactions in covalent drug design
Baillie, T. A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1832079 · Cited by 57
Zielgerichtete kovalente Inhibitoren für das Wirkstoffdesign
Baillie, T. A. (2016) · Angewandte Chemie · doi:10.1002/ange.201601091 · Cited by 44
Yip, V. L. M., Meng, X., Maggs, J. L., Jenkins, R. E., Marlot, P. T., Marson, A. G., Park, B. K., & Pirmohamed, M. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00063 · Cited by 32
Tabuchi, Y., Yang, J., & Taki, M. (2021) · Chemical Communications · doi:10.1039/d0cc08109d · Cited by 31
Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors
Zheng, J., Wu, J., Ding, X., Shen, H. C., & Zou, G. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127862 · Cited by 29
Discovery and optimization of selective RET inhibitors via scaffold hopping
Luo, Z., Wang, L., Fu, Z., Shuai, B., Luo, M., Hu, G., Chen, J., Sun, J., Wang, J., Li, J., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128149 · Cited by 28
Zhang, P., Gaffrey, M. J., Zhu, Y., Chrisler, W., Fillmore, T., Yi, L., Nicora, C., Zhang, T., Wu, H., Jacobs, J., et al. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b04258 · Cited by 29
Drug–protein adducts: past, present, and future
Baillie, T. A. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02567-8 · Cited by 25
Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping
Wang, Y., Chen, Z., Dai, M., Sun, P., Wang, C., Gao, Y., Zhao, H., Zeng, W., Shen, L., Mao, W., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.014 · Cited by 21
Uematsu, S., Tabuchi, Y., Ito, Y., & Taki, M. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00301 · Cited by 14
Chen, B., Zhang, Q., Ren, Z., Zhang, T., Yu, H., Liu, C., Yang, Y., Xu, P., & Liu, S. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04070-y · Cited by 11
Self-citationBTK-inhibitor drug covalent binding to lysine in human serum albumin using LC-MS/MS
Muste, C. A., & Gu, C. (2021) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2021.100433 · Cited by 12
Reactive Electrophiles and Metabolic Activation
Obach, R. S., & Kalgutkar, A. S. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64290-3 · Cited by 4
Reactive Electrophiles and Metabolic Activation
Obach, R. S., & Kalgutkar, A. S. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00018-8 · Cited by 4
Baccalaureate and Higher Degree Program's Accreditation Committee reports on evaluation data.
Schultz, C. M., & Niedringhaus, L. (1995) · PubMed
Metadata
- Authors
- Yang, Y., Shu, Y.-Z., & Humphreys, W. G.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Corresponding author
- Shu, Yue-Zhong
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-12-29
- Volume
- 29
- Issue
- 1
- Pages
- 109-116
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W2211426991
- Cited by
- 17
- References
- 26
- Citations by year
- 2024: 1 · 2022: 1 · 2021: 4 · 2020: 3 · 2018: 2 · 2017: 3 · 2016: 2
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Research in Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
- Keywords
- covalent inhibitors, target specificity, ibrutinib, Bruton's tyrosine kinase, hemoglobin, human serum albumin, cysteine modification, immune-mediated toxicity, early drug discovery
- MeSH terms
- Adenine, Dose-Response Relationship, Drug, Humans, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Structure-Activity Relationship, Substrate Specificity, Molecular Structure, Proteomics, Protein Kinase Inhibitors, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.